Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SENSORCAINE vs LIDOCAINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
SENSORCAINE (bupivacaine) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting depolarization and propagation of action potentials, resulting in reversible local anesthesia.
Lidocaine is a sodium channel blocker that inhibits the influx of sodium ions into cardiac Purkinje fibers and myocytes, thereby stabilizing the neuronal membrane and decreasing automaticity. It also exhibits local anesthetic effects by reversibly binding to voltage-gated sodium channels in nerve cell membranes, blocking impulse conduction.
Local anesthesia by infiltration,Peripheral nerve block,Epidural and spinal anesthesia,Caudal anesthesia,Sympathetic nerve block
Ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation),Local anesthesia (infiltration, nerve block, epidural, spinal, topical),Status epilepticus (off-label),Neonatal seizures (off-label),Digitalis-induced arrhythmias (off-label)
Epidural or caudal block: 15-30 m L of 0.5% to 1% solution (75-150 mg) every 2-4 hours as needed. Maximum single dose: 225 mg.
For ventricular arrhythmias: IV bolus 1-1.5 mg/kg, then continuous infusion 1-4 mg/min. For local anesthesia: 0.5-2% solution, max 4.5 mg/kg (300 mg) without epinephrine, 7 mg/kg (500 mg) with epinephrine.
The terminal elimination half-life of bupivacaine is approximately 2.7 hours in adults (range 1.5–5.5 hours). In neonates, the half-life is significantly prolonged (~8–12 hours) due to immature hepatic function, leading to an increased risk of toxicity.
Terminal elimination half-life 1.5-2 hours (normal hepatic function). In CHF or hepatic impairment, prolonged to 6-8 hours; in neonates, 3-6 hours. Context: rapid redistribution after IV bolus (alpha half-life ~8 min) accounts for brief clinical effect, while terminal half-life determines accumulation with infusion.
No dose adjustment required for mild to moderate impairment (GFR ≥30 m L/min). Severe impairment (GFR <30 m L/min): reduce dose by 50% and monitor for CNS toxicity.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 25% or monitor for toxicity. Lidocaine is not significantly removed by hemodialysis.
SENSORCAINE with epinephrine is not recommended for obstetrical use (paracervical block) as it can cause fetal bradycardia and death. All local anesthetics, including bupivacaine, may cause methemoglobinemia.
Sensorcaine (bupivacaine) is classified as FDA Pregnancy Category C. In the first trimester, there is a potential risk of developmental abnormalities based on animal studies showing increased fetal resorptions and delayed ossification at high doses. During the second and third trimesters, no significant teratogenic effects have been reported in humans, but the drug may cause fetal bradycardia and metabolic acidosis due to increased placental transfer near term. Use only if clearly needed.
First trimester: Limited human data, not associated with major malformations. Second and third trimesters: Fetal bradycardia and central nervous system depression possible with high maternal doses.
Sensorcaine (bupivacaine) is a long-acting amide local anesthetic. Due to high cardiac toxicity, use low concentrations (0.25-0.5%) for peripheral nerve blocks and avoid intravascular injection. Maximum dose: 2 mg/kg (with epinephrine 3 mg/kg). Not recommended for obstetrical paracervical block. Use with caution in hepatic impairment. Levobupivacaine is the S-enantiomer with lower cardiotoxicity.
Lidocaine is a class Ib antiarrhythmic and amide-type local anesthetic. For arrhythmias, use only for ventricular arrhythmias (especially post-MI) due to increased risk of asystole with atrial arrhythmias. Maximum single dose for local anesthesia: 4.5 mg/kg without epinephrine, 7 mg/kg with epinephrine. Toxic effects (CNS: perioral numbness, metallic taste, seizures; CV: hypotension, bradycardia, arrest) are dose-related. For IV use, bolus 1-1.5 mg/kg, then infusion at 1-4 mg/min. Reduce dose in heart failure, liver disease, elderly. Check for allergies to amide anesthetics (rare cross-reactivity with other amides). Use with caution with CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) and antiarrhythmics (e.g., amiodarone, procainamide).
No interactions on record
"The metabolism of Indinavir can be decreased when combined with Lidocaine."
"The serum concentration of Amiodarone can be increased when it is combined with Lidocaine."
"The metabolism of Crizotinib can be decreased when combined with Lidocaine."
SENSORCAINE and LIDOCAINE are distinct pharmacological agents. SENSORCAINE belongs to the Local Anesthetic class and is primarily used for Local anesthesia by infiltrationPeripheral nerve blockEpidural and spinal anesthesiaCaudal anesthesiaSympathetic nerve block. LIDOCAINE belongs to the Local Anesthetic / Antiarrhythmic (Class Ib) class and is primarily used for Ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation)Local anesthesia (infiltration, nerve block, epidural, spinal, topical)Status epilepticus (off-label)Neonatal seizures (off-label)Digitalis-induced arrhythmias (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SENSORCAINE carries a safety status of Category C, whereas LIDOCAINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized by the liver via conjugation with glucuronic acid; also hydrolyzed by plasma pseudocholinesterase to form pipecolylxylidine (PPX), the major metabolite.
Lidocaine is primarily metabolized in the liver via deethylation to monoethylglycinexylidide (MEGX) and then to glycinexylidide (GX) by cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. Hepatic clearance is dependent on hepatic blood flow.
SENSORCAINE (bupivacaine) is primarily metabolized in the liver via conjugation with glucuronic acid and undergoes hepatic dealkylation. Approximately 6% of the drug is excreted unchanged in the urine. The majority of the dose (about 95%) is excreted as metabolites in the urine (<10% unchanged) and the remainder in feces via biliary elimination.
Renal excretion of metabolites: 4-hydroxyxylidine (70-80% renal, 10-20% biliary/fecal), unchanged lidocaine <10% renal. Total renal elimination ~90% (as metabolites), biliary/fecal ~10%.
Bupivacaine is highly protein-bound (~95%) primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin. Binding is concentration-dependent and saturable; increased free fraction in conditions with low AAG (e.g., pregnancy, neonates, critical illness).
~70% bound primarily to alpha-1-acid glycoprotein (AAG), also to albumin. Binding is concentration-dependent and saturable; increased AAG in acute phase (e.g., MI, surgery) reduces free fraction.
Volume of distribution (Vd) at steady state is approximately 0.6–1.0 L/kg in adults (range 50–100 L). The large Vd reflects extensive tissue distribution, with rapid uptake into well-perfused organs (brain, heart, liver, kidneys).
Vd: 0.8-1.3 L/kg (adults), increased in neonates (1.5-4 L/kg). Clinical meaning: wide distribution reflects high tissue uptake, especially in well-perfused organs (brain, heart, lungs). Vd increases in CHF due to reduced cardiac output and perfusion.
Bioavailability after epidural administration is approximately 98% due to extensive vascular absorption from the epidural space. For intravenous administration, bioavailability is 100%. Oral bioavailability is low (~30–40%) due to extensive first-pass metabolism.
IV: 100%; Oral: <5% (extensive first-pass hepatic metabolism); IM: ~60-70% (variable); Epidural: complete systemic absorption (100% bioavailability into systemic circulation); Topical/transdermal: 3-10% (intact skin), ~20% (mucous membranes).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75% or avoid use; monitor levels.
Neonates and infants: 0.5-1 mg/kg by infiltration or nerve block, maximum 4 mg/kg/day. Children: 1-2 mg/kg per dose, maximum 5 mg/kg/day.
For local anesthesia: 0.5-2% solution, max 4.5 mg/kg (7 mg/kg with epinephrine). For ventricular arrhythmias: IV loading 1 mg/kg, then infusion 20-50 mcg/kg/min.
Reduce initial dose by 30-50% due to reduced clearance and increased sensitivity; titrate carefully.
Reduce doses due to decreased hepatic clearance and increased volume of distribution. Use lower loading doses (0.5-1 mg/kg) and lower infusion rates (1-2 mg/min). Monitor for CNS and cardiac toxicity.
Lidocaine injection is not indicated for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response, or for prophylaxis of ventricular arrhythmias in acute myocardial infarction. Continuous intra-arterial administration is contraindicated. Risk of severe cardiac toxicity, including asystole, with high doses or rapid infusion.
No significant food interactions. Avoid alcohol consumption as it may increase the risk of central nervous system depression.
No significant food interactions. Grapefruit juice has minimal effect on lidocaine metabolism. Avoid alcohol due to additive CNS depression. Caffeine may theoretically increase risk of arrhythmias; avoid excessive consumption.
Bupivacaine is excreted in human breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.3. Although it is considered compatible with breastfeeding, caution is advised due to the potential for cumulative local anesthetic effects in the infant, especially with repeated doses. Monitor the infant for drowsiness and feeding difficulties.
Minimal excretion into breast milk; M/P ratio 0.3-0.5. Considered compatible with breastfeeding; monitor infant for drowsiness or feeding difficulties.
No specific dosing adjustments are recommended for bupivacaine during pregnancy. However, reduced protein binding and increased volume of distribution in pregnancy may lower peak plasma concentrations. Clinicians should use the lowest effective dose and highest concentration to minimize total dose, especially for epidural or regional blocks. Monitor for prolonged effect due to decreased clearance.
Increased volume of distribution and clearance in pregnancy may require higher doses for local anesthesia; reduce dose for paracervical block to avoid fetal bradycardia; monitor maternal plasma levels.
You may experience temporary numbness or loss of sensation in the injected area.,Avoid driving or operating machinery until sensation fully returns.,Report any signs of allergic reaction, such as rash, swelling, or difficulty breathing.,Do not rub or massage the injection site to prevent spread of the drug.,Contact your healthcare provider if numbness persists beyond the expected duration.
Inform your healthcare provider if you have any history of heart disease, liver disease, or seizures before using lidocaine.,Do not exceed the prescribed dose or frequency of application; overuse can lead to serious side effects including irregular heartbeat, seizures, or breathing problems.,For topical use, avoid applying to large areas of skin, broken or irritated skin, or near eyes and mucous membranes.,Seek immediate medical help if you experience symptoms of toxicity such as blurred vision, ringing in ears, slurred speech, confusion, severe dizziness, or slow/irregular heartbeat.,Avoid consuming alcohol while using lidocaine, as it may increase the risk of side effects.,Do not drive or operate heavy machinery if you experience dizziness, drowsiness, or blurred vision after using lidocaine.